Navigation Links
Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES)
Date:2/17/2011

DURHAM, N.C., Feb. 17, 2011 /PRNewswire/ --  Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial.  Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

The MiStent DES employs Micell's proprietary supercritical fluid technology which applies a precisely controlled absorbable polymer - active drug (sirolimus) matrix onto a cobalt-chromium stent.  The polymer dissolves and releases the drug into the surrounding tissue in a controlled manner, designed to optimize dosing of the drug throughout the affected artery.  In GLP pre-clinical trials, the drug completely elutes and the polymer is eliminated from the stent within 45 to 60 days in vivo, resulting in a bare-metal stent.

DESSOLVE II is a prospective, controlled, 2:1 unbalanced randomized, multi-center study of approximately 270 patients.  Patients will be enrolled at 26 clinical sites in Europe, New Zealand and Australia.  Candidates for the trial are patients with documented stable or unstable angina pectoris or ischemia.  The primary endpoint is superiority of MiStent DES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor® DES, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm long stent.

Along with secondary clinical endpoints such as major adverse c
'/>"/>

SOURCE Micell Technologies Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014   Royal Philips ... announced it has received 510(k) clearance from the ... precision planning application for Transcatheter Aortic-Valve Implantation (TAVI) ... provides interventionalists with pre-procedural, high-precision positioning to treat ... planning application is available as part of Philips ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Indiana blocked the sale of more ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Calif., Oct. 28 Watson Pharmaceuticals, Inc. (NYSE: ... announced today that its subsidiary Watson Laboratories, Inc. ... on outstanding patent litigation related to Watson,s Oxytrol® ... August 19, 2008, Barr submitted an Abbreviated New ...
... 27 Cambrex Corporation (NYSE: CBM ) announced that third quarter 2009 financial results will be ... conference call to discuss the third quarter 2009 financial results. , , ... 2009 Earnings Conference Call, When: ... 1-888-634-4003 for U.S., ...
Cached Medicine Technology:Watson and Barr Settle Lawsuit Over Oxytrol(R) 2
(Date:8/21/2014)... DURHAM, NC -- Researchers have pinpointed the environmental source ... in Southern California for decades. It literally grows on ... project of a 13-year-old girl, who spent the summer ... Angeles hardest hit by infections of the fungus named ... Cryptococcus , which encompasses a number of species ...
(Date:8/21/2014)... California (PRWEB) August 21, 2014 The ... initial plans for entertainment and programming for its inaugural ... On Sunday, October 12, 2014, from 11 a.m. to ... closed to all cars and the downtown will be ... activities, curated by Community Arts Resources (CARS), for all ...
(Date:8/21/2014)... (HealthDay News) -- Not only is eating better and exercising ... of health-care dollars a year, a new study finds. ... health sciences at Wake Forest Baptist Medical Center in Winston-Salem, ... 2 diabetes patients. Participants ranged in age ... an intensive "lifestyle change program" focused on diet and exercise, ...
(Date:8/21/2014)... seniors, dimming vision may be tied to poorer survival, new ... aged 65 to 84, who were assessed when they enrolled ... later. Vision loss over time was associated with an ... period, the researchers reported. Although the study couldn,t prove ... University in West Lafayette, Ind., offered up some theories on ...
(Date:8/21/2014)... The W. Montague Cobb/ NMA Health ... voice in the elimination of health disparities, honored ... 112th National Medical Association’s (NMA) Annual Convention and ... Ruffin, Ph.D, former Director of the National Institute ... career and innovations have had a significant impact ...
Breaking Medicine News(10 mins):Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2
... is associated with a statistically significant increase in cancer risk ... of the breast, liver, rectum, and upper aero-digestive tract combined, ... of the Journal of the National Cancer Institute. ... known about the impact of low to moderate alcohol consumption ...
... are sent to a cardiologist to go through a standard ... evidence of coronary artery disease which is the most common ... in men, and these women are sent home with little ... complaining of similar symptoms and are more likely to develop ...
... Postpartum depression is a seriousand often undiagnosedcondition affecting about ... the causes might include personal history of depression, stressful ... support. Left untreated, it can have lasting negative effects ... development. , In the first study of ...
... And that can pose a big public health threat, ... Following their release from Texas prisons, only 5 percent ... to treat their condition within the necessary 10 days, ... [antiretroviral therapy] at this time are at increased risk ...
... Experts agree that field needs more rigorous trials to aid ... of the guidelines for cardiac care issued by the American ... supported by the kind of gold-standard evidence that doctors respect ... come from heretics crying in the wilderness. One author of ...
... Telekenex, Inc ("Telekenex"), today announced it has ... MPLS network over the weekend from Straitshot Communications ... the challenge and worked straight through the weekend ... its network. One of these companies, Evergreen ...
Cached Medicine News:Health News:Million women study shows even moderate alcohol consumption associated with increased cancer risk 2Health News:Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain 2Health News:Diabetes a risk factor for postpartum depression 2Health News:Most HIV-Infected Prisoners Go Untreated After Release 2Health News:Weak Evidence Backs Most Heart Guidelines, Report Finds 2Health News:Weak Evidence Backs Most Heart Guidelines, Report Finds 3Health News:Evergreen Healthcare and Others Successfully Migrate to the Telekenex Network From Straitshot 2
Single-Piece PMMA Intraocular Lenses....
Single Piece PMMA Lens (Refractive and Bifocal). Anterior chamber Lens....
Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
STABIBAG Hydrophilic Acrylic Lens....
Medicine Products: